These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26755050)

  • 1. NCI-60 Cell Line Screening: A Radical Departure in its Time.
    Chabner BA
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26755050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
    Kong D; Yamori T
    Bioorg Med Chem; 2012 Mar; 20(6):1947-51. PubMed ID: 22336246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCI-MATCH launch highlights new trial design in precision-medicine era.
    McNeil C
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142446
    [No Abstract]   [Full Text] [Related]  

  • 4. 40 years of the war on cancer.
    Science; 2011 Mar; 331(6024):1540-4. PubMed ID: 21436435
    [No Abstract]   [Full Text] [Related]  

  • 5. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
    Christian MC; Pluda JM; Ho PT; Arbuck SG; Murgo AJ; Sausville EA
    Semin Oncol; 1997 Apr; 24(2):219-40. PubMed ID: 9129691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidiabetic agents: past, present and future.
    Mehanna A
    Future Med Chem; 2013 Mar; 5(4):411-30. PubMed ID: 23495689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NCI Program for Natural Product Discovery: A Publicly-Accessible Library of Natural Product Fractions for High-Throughput Screening.
    Thornburg CC; Britt JR; Evans JR; Akee RK; Whitt JA; Trinh SK; Harris MJ; Thompson JR; Ewing TL; Shipley SM; Grothaus PG; Newman DJ; Schneider JP; Grkovic T; O'Keefe BR
    ACS Chem Biol; 2018 Sep; 13(9):2484-2497. PubMed ID: 29812901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NCI-MATCH trial pushes cancer umbrella trial paradigm.
    Mullard A
    Nat Rev Drug Discov; 2015 Aug; 14(8):513-5. PubMed ID: 26228747
    [No Abstract]   [Full Text] [Related]  

  • 10. Modernizing the NCI60 Cell Line Screen for Phenotypic Drug Discovery in the 21st Century.
    Colombo GM; Corsello SM
    Cancer Res; 2024 Aug; 84(15):2397-2399. PubMed ID: 39086314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emil Frei III, 1924-2013.
    Holland JF; Freireich EJ
    J Clin Oncol; 2013 Oct; 31(30):3727-30. PubMed ID: 24019548
    [No Abstract]   [Full Text] [Related]  

  • 12. Anticancer drug development at the US National Cancer Institute.
    Takimoto CH
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S29-33. PubMed ID: 12819935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Network pharmacology for cancer drug discovery: are we there yet?
    Azmi AS
    Future Med Chem; 2012 May; 4(8):939-41. PubMed ID: 22650234
    [No Abstract]   [Full Text] [Related]  

  • 14. Investigational trials of anticancer drugs: establishing safeguards for experimentation.
    Chabner BA; Wittes R; Hoth D; Hubbard S
    Public Health Rep; 1984; 99(4):355-60. PubMed ID: 6431482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Cancer Institute Formulary: A Public-Private Partnership Providing Investigators Access to Investigational Anticancer Agents.
    Cristofaro JV; Ansher SS; Zwiebel JA; Ivy P; Conley B; Abrams JS; Doroshow JH
    Clin Pharmacol Ther; 2017 May; 101(5):616-618. PubMed ID: 27981567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Society of Clinical Oncology Developing First Clinical Trial.
    Brower V
    J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
    [No Abstract]   [Full Text] [Related]  

  • 17. Web-based tools for mining the NCI databases for anticancer drug discovery.
    Fang X; Shao L; Zhang H; Wang S
    J Chem Inf Comput Sci; 2004; 44(1):249-57. PubMed ID: 14741034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel drugs for promising targets.
    Martell RE; Brooks DG; Wang Y; Wilcoxen K
    Clin Ther; 2013 Sep; 35(9):1271-81. PubMed ID: 24054704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Historical aspect of molecular-targeted therapy for cancer].
    Sone S; Otsuka K; Tobiume M; Tada H
    Nihon Rinsho; 2010 Oct; 68(10):1787-95. PubMed ID: 20954319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NCI Developmental Therapeutics Program.
    Collins JM
    Clin Adv Hematol Oncol; 2006 Apr; 4(4):271-3. PubMed ID: 16728938
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.